ROLE OF GENDER SPECIFICS IN MYOCARDIAL REMODELLING, CARDIOVASCULAR COMPLICATIONS DEVELOPMENT AND EFFICACY OF PHARMACOTHERAPY IN HEART FAILURE PATIENTS AFTER CARDIAC SURGERY

Aim. To assess gender influence on myocardial remodelling, pharmacotherapy efficacy and complications development in chronic heart failure patients (CHF) post cardiac surgery.

Material and methods. In the study, 87 patients included, both genders, with CHF, who had been planned for cardiac surgery. All underwent standard investigations and CHF treatment, as other pathologies. Myocardium specimens from the right atrium appendage (RAA) were collected during surgery, investigated with general histology, immune histochemistry (expression of MMP-9, TIMP-1 and р38αMAPK) methods. For the evaluation of treatment influence on myocardium, intervention groups were selected: enalapril and metoprolol, perindopril and amlodipine (Prestance®, “Les Laboratoires Servier”, France). In all participants, at 10-14 day post surgery, the rate of complications was evaluated, by groups. At least one complication led to selection the participant as adverse in-hospital outcome. The relations were studied, of post-surgery complications with EchoCG data and morphological changes in LAA myocardium, taken the gender and left ventricle ejection fraction (LVEF).

Results. In cardiac surgery group with heart failure and preserved LVEF (HFpEF) with the increase of CHF functional class, normal LVEF remained, and there was worsening of the LV diastolic function. In HFpEF males there was decrease of EF with transition to “grey zone” by III functional class, and eccentric remodeling predominated with unchanged diastolic function. In HF mid-range EF group, regardless of gender, there was eccentric LV remodelling. In RAA myocardium of women there was lower grade of myocardial fibrosis and mononuclear areas of infiltration, and there was higher rate of cardiovascular as extracardiac complications. High grade of MMP-9 in RAA revealed in the group of HF mid-range EF and adverse outcome, regardless gender, and increased expression of р38αMAPK in females of thisgroup. In perindopril and amlodipine group there was lower grade of MMP-9 and р38αMAPK expression.

Conclusion. The study demonstrated gender differences in remodelling of myocardium in HFpEF patients. This makes to consider female gender, HF midrange EF, MMP-9 expression in RAA myocardium, as prognostic markers of surgery adverse outcome. Combination of perindopril and amlodipine demonstrated protective influence on myocardium, with more prominent effect in females.

1. Ginghina C, Botezatu CD, Serban M, Jurcut R. A personalized medicine target: heart failure in women. Journal of Medicine and Life 2011; 4 (3): 280-86.

2. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nature reviews. Cardiology 2017; 1-12. DOI:10.1038/nrcardio.2017.65.

3. Zhao Z, Wang H, Jessup JA, et al. Role of estrogen in diastolic dysfunction. Am J Physiol Heart Circ Physiol 2014; 306: 628-40. DOI:10.1152/ajpheart.00859.2013.

4. Keller KM, Howlett SE. Sex differences in the biology and pathology of the aging heart. Can J Cardiol 2016; 32 (9): 1065-73. DOI:10.1016/j.cjca.2016.03.017.

5. Regitz-Zagrosek V. Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nature Reviews/Drug Discovery 2006; 5: 425-39. DOI: 10.1038/nrd2032.

6. Heer T, Hochadel M, Schmidt K, et al. Sex Differences in Percutaneous Coronary Intervention—Insights From the Coronary Angiography and PCI Registry of the German Society of Cardiology. Am Heart Assoc. 2017; 6 (3): e004972. DOI: 10.1161/JAHA.116.004972.

7. Mikhail GW. Coronary revascularisation in women. Heart 2006; 92 (3): 19-23. DOI: 10.1136/hrt.2005.070359.

8. Mareev VYu, Аgeev FT, Аrutyunov GP, et al. National recommendations of OSSN, RСO and RNMOT on diagnosis and treatment of CHF. Zhurnal Serdechnaya Nedostatochnost’ 2013; 7 (81): 379-472. (In Russ.) Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П., Коротеев А.В с соавторами. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН. Журнал Сердечная Недостаточность 2013; 7 (81): 379-472.

9. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Russ J Cardiol 2017; 1 (141): 7-81. (In Russ.) Рекомендации ESC по диагностике и лечению острой и хронической сердечной недостаточности 2016. Российский кардиологический журнал 2017; 1 (141): 7-81. DOI: 10.15829/1560-4071-2017-1-7-81.

10. Piro M, Bona RD, Abbate A, et al. Sex-Related Differences in Myocardial Remodeling. J Am Coll Cardiol 2010; 55: 1057-65. DOI:10.1016/j.jacc.2009.09.065.

11. Regitz-Zagrosek V, Seeland U. Sex and gender differences in myocardial hypertrophy and heart failure. Wien Med Wochenschr 2011; 161 (5-6): 109-16. DOI 10.1007/s10354-011-0892-8.

12. Spinale FG. Matrix Metalloproteinases: Regulation and Dysregulation in the Failing Heart. Circ Res. 2002; 90: 520-30. DOI: 10.1161/01.RES.0000013290.12884.A3.

13. Morishita T, Uzui H, Mitsuke Y, et al. Association between matrix metalloproteinase-9 and worsening heart failure events in patients with chronic heart failure ESC Heart Failure 2017; 1-10. DOI: 10.1002/ehf2.12137.

14. Liskova YuV, Salikova SP, Stadnikov АА. Extracellular matrix remodeling myocardium of the left ventricle rats with experimental heart failure after perindopril and melatonin administration. ZHurnal Kardiologiya 2014; 54 (9): 52-6. (In Russ.) Лискова Ю.В., Саликова С.П., Стадников А.А. Особенности ремоделирования внеклеточного матрикса миокарда левого желудочка крыс с экспериментальной сердечной недостаточностью при введении периндоприла и мелатонина. Журнал Кардиология 2014; 54 (9): 52-6.

15. Mason RP, Marche P, Hintze TH. Novel Vascular Biology of Third-Generation L-Type Calcium Channel Antagonists Ancillary. Actions of Amlodipine. Arterioscler Thromb Vasc Biol. 2003; 23: 2155-63.

16. Muslin AJ. MAPK Signaling in Cardiovascular Health and Disease: Molecular Mechanisms and Therapeutic Targets. Clin Sci (Lond). 2008; 115 (7): 203-18. DOI: 10.1042/CS20070430.

17. Umemoto S. Kawahara S, Hashimoto R, et al. Different effects of amlodipine and enalapril on the mitogen-activated protein kinase/extracellular signal-regulated kinase kinaseextracellular signal-regulated kinase pathway for induction of vascular smooth muscle cell differentiation in vivo. Hypertens Res. 2006; 29 (3): 179-86.